A multicenter phase 3 trial of lobeline sulfate for smoking cessation.
To evaluate the safety and efficacy of sublingual lobeline sulfate for smoking cessation. A multicenter (3 sites), double-blind, parallel, placebo-controlled, phase 3 smoking cessation trial of sublingual formulation of lobeline sulfate. A total of 750 smokers (250 per site) were randomized to either treatment (lobeline sulfate) or placebo with individual smoking cessation counseling lasting up to approximately 10 minutes. Efficacy revealed no statistical significance (P = 0.62) for lobeline sulfate as a smoking cessation aid. Sublingual formulation of lobeline sulfate does not appear to be an effective smoking cessation aid.